tubulin inhibitor24

Tubulin inhibitor 24 is a potent compound that inhibits tubulin polymerization.

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

Eg5 Inhibitor V, trans-24, is a specific and potent Eg5 inhibitor with an IC50 value of 0.65 μM, suitable for use in cancer research.

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

BRD4 Inhibitor-24 is a BRD4 small molecule inhibitor with antitumor activity.

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM, which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. As a microtubule destabilizer, Tubulin inhibitor 14 has potential tumor-selective, anti-angiogenic, and vascular-destructive properties [1].

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2/M phase.

Tubulin Inhibitor 28 (compound 2g), with an IC50 value of 1.2 μM, is a potent inhibitor of tubulin that exhibits significant anti-proliferative activity against MCF-7 cells [1].

Tubulin Inhibitor 21 (compound 6f), a hybrid based on chalcone and melatonin, exhibits potent tubulin inhibition properties. It demonstrates significant cytotoxic activity against SW480 cells (IC 50 =0.26 μM) while showing lesser effects on nonmalignant cells [1].

Tubulin inhibitor 7 is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines (tubulin polymerization (IC50: 0.52 μM), K562 cell growth (IC50: 11 nM)).

Tubulin inhibitor 12 (Hit 9) is a recently developed compound with potent tubulin inhibitory effects (IC50 = 25.3 μM) and significant anti-tumor and anti-proliferative activities, making it a promising candidate for cancer treatment [1].

Tubulin inhibitor 26 (compound 3c) is an indazole derivative and a potent tubulin inhibitor with low nanomolar potency against HepG2, HCT116, SW620, HT29, and A549 cancer cell lines. It inhibits tumor cells in the G2 M phase, induces cell apoptosis, and suppresses tumor growth in vivo without affecting mice body weight [1].

Tubulin Inhibitor 34 (compound b5), a potent anticancer agent, inhibits tubulin polymerization and induces G2/M arrest and apoptosis. The compound demonstrates significant antivascular and antitumor activity [1].

Tubulin inhibitor 16 is a potent tubulin inhibitor that exhibits antiproliferative activity and cytotoxicity in HepG2 cells [1].

Tubulin polymerization-IN-24 (compound HMBA) is a potent inhibitor of tubulin polymerization, increasing GTP hydrolysis rate and inhibiting microtubule assembly. It induces apoptosis and cell cycle arrest in the G2 M phase, and inhibits the proliferation of MCF-7 cells [1].

Tubulin Inhibitor 31 is a potent compound with an inhibitory concentration (IC 50) of 4 µM, demonstrating significant anti-proliferative activity and the ability to inhibit HUVEC migration.

Tubulin Inhibitor 13 (E27) effectively inhibits tubulin polymerization with an IC50 of 16.1 μM. This compound also restricts cancer cell migration and invasion, promotes apoptosis, and exhibits notable anticancer activity [1].

Tubulin inhibitor 15 is a potent tubulin inhibitor with antiproliferative activity, exhibiting cytotoxicity in HepG2 cells [1].

Tubulin inhibitor 25 is a potent tubulin inhibitor (IC50: 0.98 μM) that significantly inhibits HT29 cells, impedes cell migration and microtubule formation, and contributes to anti-angiogenesis.

HIV-1 inhibitor-24 (compound S-12a) is a potent inhibitor of HIV-1 reverse transcription (HIV-1 RT) with an IC50 of 9.5 nM. It exhibits a high antiviral effect on wild-type HIV-1, showing an EC50 value of 1.6 nM and low cytotoxicity (CC50 on MT-4 cells). HIV-1 inhibitor-24 was well tolerated in mice at a dose of 2 g kg and demonstrated a significant cardiovascular safety profile.

Tubulin Inhibitor 30, exhibiting an IC50 value of 0.52 μM, functions as an inhibitor of tubulin assembly. Additionally, it can induce ferroptosis.

Tubulin inhibitor 18 (compound 5j) is a highly potent chalcone compound that effectively inhibits tubulin, making it a promising candidate for cancer research [1].

Tubulin inhibitor 22 (compound 4c) is a potent tubulin inhibitor exhibiting anti-angiogenic and anti-cancer activity, which blocks the cell cycle of MGC-803 cells in the G2 M phase and induces Caspase-mediated apoptosis through mitochondrial dysfunction in a dose-dependent manner.

PKI PKA Inhibitor (5-24) is a synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki= 2.3 nM) derived from the active site of the skeletal muscle inhibitor protein.1It mimics the protein substrate by binding to the catalytic site through the arginine-cluster basic subsite.1The prominent enzyme-substrate interaction site occurs where PKA catalytic subunit residues Tyr235and Phe239form a sandwich-like structure with residue Phe10of PKI (5-24).2

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that disrupts tubulin assembly by binding at the colchicine site (IC50 = 1.2 μM), and exhibits antiproliferative effects on MCF-7 cells with an IC50 value of 7.5 μM. [1].

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM) that exhibits anticancer activities and induces cell apoptosis[1].

Tubulin inhibitor 23 is a potent tubulin inhibitor (IC50: 4.8 μM) that exhibits antiangiogenic effects in a dose-dependent manner and induces apoptosis. This compound shows potential for leukemia research.

Tubulin inhibitor 20 (compound 1) exhibits significant potential for cancer research as a potent tubulin inhibitor [1].

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound exhibiting strong tubulin inhibitory activity, making it valuable for cancer research [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].